RCM
BMY icon

Riverhead Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Riverhead Capital Management’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$11.4M Buy
225,463
+70,818
+46% +$3.33M 0.42% 42
2019
Q2 		$7.01M Buy
154,645
+113,695
+278% +$5.3M 0.26% 94
2019
Q1 		$1.95M Buy
40,950
+20,300
+98% +$1.01M 0.08% 313
2018
Q4 		$1.07M Sell
20,650
-6,890
-25% -$370K 0.05% 431
2018
Q3 		$1.71M Sell
27,540
-350
-1% -$20.8K 0.06% 349
2018
Q2 		$1.54M Sell
27,890
-861
-3% -$46.5K 0.06% 357
2018
Q1 		$1.82M Buy
28,751
+5,217
+22% +$336K 0.08% 299
2017
Q4 		$1.44M Buy
23,534
+8,784
+60% +$549K 0.06% 342
2017
Q3 		$940K Buy
+14,750
New +$861K 0.04% 419
2017
Q1 		– Sell
-16,082
Closed -$940K – 1520
2016
Q4 		$940K Sell
16,082
-62,018
-79% -$3.39M 0.06% 355
2016
Q3 		$4.21M Buy
78,100
+74,492
+2,065% +$4.79M 0.27% 107
2016
Q2 		$41K Sell
3,608
-563,253
-99% -$39.8M ﹤0.01% 1348
2016
Q1 		$36.2M Sell
566,861
-215,433
-28% -$13.6M 0.51% 42
2015
Q4 		$53.8M Buy
782,294
+23,247
+3% +$1.54M 0.78% 14
2015
Q3 		$44.9M Buy
759,047
+259,253
+52% +$16.4M 0.71% 21
2015
Q2 		$33.3M Buy
499,794
+194,372
+64% +$12.8M 0.5% 47
2015
Q1 		$19.7M Sell
305,422
-7,975
-3% -$499K 0.3% 102
2014
Q4 		$18.5M Buy
313,397
+268
+0.1% +$15.1K 0.28% 101
2014
Q3 		$16M Buy
313,129
+32,003
+11% +$1.6M 0.28% 101
2014
Q2 		$13.6M Buy
281,126
+67,961
+32% +$3.35M 0.26% 107
2014
Q1 		$11.1M Buy
213,165
+28,849
+16% +$1.54M 0.24% 109
2013
Q4 		$9.8M Buy
184,316
+10,016
+6% +$510K 0.26% 115
2013
Q3 		$8.06M Buy
174,300
+1,566
+0.9% +$68.7K 0.26% 103
2013
Q2 		$7.72M Buy
+172,734
New +$7.5M 0.26% 104

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Riverhead Capital Management's BMY Position: Q3 2019 in Review

Riverhead Capital Management increased its Bristol-Myers Squibb (BMY) stake by 46% in Q3 2019, buying an estimated $3.33M and bringing the position to 225,463 shares worth $11.4M. The position accounts for 0.42% of the portfolio, ranked #42.

Riverhead Capital Management first reported a position in BMY in Q2 2013 and has held it in 24 quarters since. The position peaked at $53.8M in Q4 2015. 1,814 funds tracked by Wall St. Rank hold BMY as of Q3 2019.

  • Riverhead Capital Management held 225,463 shares of Bristol-Myers Squibb worth $11.4M as of Q3 2019.
  • Riverhead Capital Management bought 70,818 Bristol-Myers Squibb shares in Q3 2019, an estimated $3.33M.
  • Bristol-Myers Squibb made up 0.42% of Riverhead Capital Management's portfolio in Q3 2019, its #42 holding.
  • Riverhead Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 24 quarters since.
  • Riverhead Capital Management's Bristol-Myers Squibb position peaked at $53.8M in Q4 2015.
  • 1,814 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.